In terms of DDR’s specific clinical significance in breast cancer treatment, recent studies have shown that the benefit of PARP inhibitors extends beyond patients with germline BRCA1/2-associated metastatic breast cancer to those with somatic BRCA1/2 variants and to those with germline PALB2 alterations (23). The gene discussed is PALB2; the disease is breast cancer.